Your browser doesn't support javascript.
loading
Anticoagulation in Patients With Device-Detected Atrial Fibrillation With and Without a Prior Stroke or Transient Ischemic Attack: The NOAH-AFNET 6 Trial.
Diener, Hans Christoph; Becher, Nina; Sehner, Susanne; Toennis, Tobias; Bertaglia, Emanuele; Blomstrom-Lundqvist, Carina; Brandes, Axel; Beuger, Vincent; Calvert, Melanie; Camm, A John; Chlouverakis, Gregory; Dan, Gheorghe-Andrei; Dichtl, Wolfgang; Fierenz, Alexander; Goette, Andreas; de Groot, Joris R; Hermans, Astrid; Lip, Gregory Y H; Lubinski, Andrzej; Marijon, Eloi; Merkely, Béla; Mont, Lluís; Nikorowitsch, Julius; Ozga, Ann-Kathrin; Rajappan, Kim; Sarkozy, Andrea; Scherr, Daniel; Schnabel, Renate B; Schotten, Ulrich; Simantirakis, Emmanuel; Vardas, Panos; Wichterle, Dan; Zapf, Antonia; Kirchhof, Paulus.
Affiliation
  • Diener HC; Department of Neuroepidemiology Institute for Medical Informatics, Biometry and Epidemiology (IMIBE), University Duisburg-Essen Essen Germany.
  • Becher N; Department of Cardiology University Heart & Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf Hamburg Germany.
  • Sehner S; German Center for Cardiovascular Research (DZHK) Partner Site Hamburg/Kiel/Luebeck Hamburg Germany.
  • Toennis T; Institute of Medical Biometry and Epidemiology University Medical Centre Hamburg-Eppendorf Hamburg Germany.
  • Bertaglia E; Department of Cardiology University Heart & Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf Hamburg Germany.
  • Blomstrom-Lundqvist C; German Center for Cardiovascular Research (DZHK) Partner Site Hamburg/Kiel/Luebeck Hamburg Germany.
  • Brandes A; Cardiology Unit Camposampiero Hospital - AULSS Euganea Padua Italy.
  • Beuger V; Department of Medical Science Uppsala University Uppsala Sweden.
  • Calvert M; Department of Cardiology, School of Medical Sciences, Faculty of Medicine and Health Örebro University Örebro Sweden.
  • Camm AJ; Department of Cardiology Esbjerg Hospital, University Hospital of Southern Denmark Esbjerg Denmark.
  • Chlouverakis G; Atrial Fibrillation Network (AFNET) Muenster Germany.
  • Dan GA; Atrial Fibrillation Network (AFNET) Muenster Germany.
  • Dichtl W; Center for Patient Reported Outcomes Research Institute of Applied Health Research, University of Birmingham Birmingham United Kingdom.
  • Fierenz A; NIHR Birmingham Biomedical Research Center and NIHR Applied Research Collaboration West Midlands University of Birmingham Birmingham United Kingdom.
  • Goette A; Cardiovascular and Cell Sciences Research Institute, St. George's University of London London United Kingdom.
  • de Groot JR; Biostatistics Laboratory, School of Medicine University of Crete Crete Greece.
  • Hermans A; Medicine University "Carol Davila" Colentina University Hospital Bucharest Romania.
  • Lip GYH; Department of Internal Medicine III, Cardiology and Angiology Innsbruck Medical University Innsbruck Austria.
  • Lubinski A; Institute of Medical Biometry and Epidemiology University Medical Centre Hamburg-Eppendorf Hamburg Germany.
  • Marijon E; Atrial Fibrillation Network (AFNET) Muenster Germany.
  • Merkely B; Department of Cardiology and Intensive Care Medicine St Vincenz-Hospital Paderborn Paderborn Germany.
  • Mont L; Otto-von-Guericke Universität Magdeburg Magdeburg Germany.
  • Nikorowitsch J; The Heart Center, Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers University of Amsterdam Amsterdam the Netherlands.
  • Ozga AK; Department of Cardiology and Physiology Maastricht University Maastricht the Netherlands.
  • Rajappan K; Liverpool Center for Cardiovascular Science at University of Liverpool Liverpool John Moores University and Liverpool Heart & Chest Hospital Liverpool United Kingdom.
  • Sarkozy A; Danish Center for Health Services Research, Department of Clinical Medicine Aalborg University Aalborg Denmark.
  • Scherr D; Department of Cardiology and Internal Diseases Medical University of Gdansk Gdansk Poland.
  • Schnabel RB; Cardiology Division European Georges Pompidou Hospital Paris France.
  • Schotten U; Heart and Vascular Center Semmelweis University Budapest Hungary.
  • Simantirakis E; Hospital Clínic Universitat de Barcelona Barcelona Catalonia Spain.
  • Vardas P; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) Barcelona Catalonia Spain.
  • Wichterle D; Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (CIBERCV) Madrid Spain.
  • Zapf A; Department of Cardiology University Heart & Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf Hamburg Germany.
  • Kirchhof P; German Center for Cardiovascular Research (DZHK) Partner Site Hamburg/Kiel/Luebeck Hamburg Germany.
J Am Heart Assoc ; 13(17): e036429, 2024 Sep 03.
Article de En | MEDLINE | ID: mdl-39190564
ABSTRACT

BACKGROUND:

Short and rare episodes of atrial fibrillation (AF) are commonly detected using implanted devices (device-detected AF) in patients with prior stroke or transient ischemic attack (TIA). The effectiveness and safety of oral anticoagulation in patients with prior stroke or TIA and device-detected AF but with no ECG-documented AF is unclear. METHODS AND

RESULTS:

This prespecified analysis of the NOAH-AFNET 6 (Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes) trial with post hoc elements assessed the effect of oral anticoagulation in patients with device-detected AF with and without a prior stroke or TIA in the randomized, double-blind, double-dummy NOAH-AFNET 6 trial. Outcomes were stroke, systemic embolism, and cardiovascular death (primary outcome) and major bleeding and death (safety outcome). A prior stroke or TIA was found in 253 patients with device-detected AF randomized in the NOAH-AFNET 6 (mean age, 78 years; 36.4% women). There was no treatment interaction with prior stroke or TIA for any of the primary and secondary time-to-event outcomes. In patients with a prior stroke or TIA, 14 out of 122 patients experienced a primary outcome event with anticoagulation (5.7% per patient-year). Without anticoagulation, there were 16 out of 131 patients with an event (6.3% per patient-year). The rate of stroke was lower than expected (anticoagulation 4 out of 122 [1.6% per patient-year]; no anticoagulation 6 out of 131 [2.3% per patient-year]). Numerically, there were more major bleeding events with anticoagulation in patients with prior stroke or TIA (8 out of 122 patients) than without anticoagulation (2 out of 131 patients).

CONCLUSIONS:

Anticoagulation appears to have ambiguous effects in patients with device-detected AF and a prior stroke or TIA in this hypothesis-generating analysis of the NOAH-AFNET 6 in the absence of ECG-documented AF, partially due to a low rate of stroke without anticoagulation.
Sujet(s)
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Fibrillation auriculaire / Accident ischémique transitoire / Accident vasculaire cérébral / Anticoagulants Limites: Aged / Aged80 / Female / Humans / Male Langue: En Journal: J Am Heart Assoc Année: 2024 Type de document: Article Pays de publication: Royaume-Uni

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Fibrillation auriculaire / Accident ischémique transitoire / Accident vasculaire cérébral / Anticoagulants Limites: Aged / Aged80 / Female / Humans / Male Langue: En Journal: J Am Heart Assoc Année: 2024 Type de document: Article Pays de publication: Royaume-Uni